Management of metastatic bone disease of melanoma

被引:1
作者
Chen, Wenyan [1 ,2 ,3 ]
Yang, Chen [1 ,2 ,3 ]
Chen, Biqi [1 ,2 ,3 ]
Xi, Mian [1 ,2 ,3 ]
Chen, Baoqing [1 ,2 ,3 ]
Li, Qiaoqiao [1 ,2 ,3 ,4 ]
机构
[1] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Dept Radiat Oncol, State Key Lab Oncol South China,Canc Ctr, Guangzhou, Peoples R China
[2] Guangdong Esophageal Canc Res Inst, Guangzhou, Peoples R China
[3] Guangdong Prov Clin Res Ctr Canc, Guangzhou, Peoples R China
[4] Sun Yat Sen Univ, Dept Radiat Oncol, Canc Ctr, 651 Dongfeng East Rd, Guangzhou 510060, Peoples R China
关键词
bone metastases; melanoma; radiotherapy; surgery; PALLIATIVE RADIOTHERAPY TRIALS; CYTOCHROME-C RELEASE; SKELETAL METASTASES; PROGNOSTIC-FACTORS; DOUBLE-BLIND; PHASE-III; IONIZING-RADIATION; ANTITUMOR IMMUNITY; ZOLEDRONIC ACID; LUNG-CARCINOMA;
D O I
10.1097/CMR.0000000000000937
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
One of the most aggressive tumors arising from the skin, mucosa, and uvea is malignant melanoma, which easily metastasizes. Bone tissue is one of the most typical locations for distant metastasis, and around 5%-20% of patients eventually acquired skeletal metastases. For decades, the incidence of bone metastases was higher, bringing greater burden on the family, society, and healthcare system owing to the progress of targeted therapy and immunotherapy, which prolonging the survival time substantially. Moreover, bone metastases result in skeletal-related events, which influence the quality of life, obviously. Appropriate intervention is therefore crucial. To obtain the optimum cost-effectiveness, existing treatment algorithm must be integrated, which is still controversial. We have aimed to throw light on current views concerning the formation, biological and clinical features, and treatment protocol of melanoma bone metastases to guide the decision-making process.
引用
收藏
页码:22 / 30
页数:9
相关论文
共 103 条
  • [1] Immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy alone versus immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy in combination with anti-RANKL denosumuab in malignant melanoma: a retrospective analysis at a tertiary care center
    Afzal, Muhammad Z.
    Shirai, Keisuke
    [J]. MELANOMA RESEARCH, 2018, 28 (04) : 341 - 347
  • [2] Roles of the RANKL-RANK axis in antitumour immunity - implications for therapy
    Ahern, Elizabeth
    Smyth, Mark J.
    Dougall, William C.
    Teng, Michele W. L.
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2018, 15 (11) : 676 - 693
  • [3] Co-administration of RANKL and CTLA4 Antibodies Enhances Lymphocyte-Mediated Antitumor Immunity in Mice
    Ahern, Elizabeth
    Harjunpaa, Heidi
    Barkauskas, Deborah
    Allen, Stacey
    Takeda, Kazuyoshi
    Yagita, Hideo
    Wyld, David
    Dougall, William C.
    Teng, Michele W. L.
    Smyth, Mark J.
    [J]. CLINICAL CANCER RESEARCH, 2017, 23 (19) : 5789 - 5801
  • [4] Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired
    Ahmadzadeh, Mojgan
    Johnson, Laura A.
    Heemskerk, Bianca
    Wunderlich, John R.
    Dudley, Mark E.
    White, Donald E.
    Rosenberg, Steven A.
    [J]. BLOOD, 2009, 114 (08) : 1537 - 1544
  • [5] Combination of denosumab and immune checkpoint inhibition: experience in 29 patients with metastatic melanoma and bone metastases
    Angela, Yenny
    Haferkamp, Sebastian
    Weishaupt, Carsten
    Ugurel, Selma
    Becker, Juergen C.
    Oberndoerfer, Florian
    Alar, Vesna
    Satzger, Imke
    Gutzmer, Ralf
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2019, 68 (07) : 1187 - 1194
  • [6] [Anonymous], 2022, Melanoma: Cutaneous, Version 2.2022 - January 26, 2022. NCCN clinical practice guidelines in oncology
  • [7] Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
    Ascierto, Paolo A.
    McArthur, Grant A.
    Dreno, Brigitte
    Atkinson, Victoria
    Liszkay, Gabrielle
    Di Giacomo, Anna Maria
    Mandala, Mario
    Demidov, Lev
    Stroyakovskiy, Daniil
    Thomas, Luc
    de la Cruz-Merino, Luis
    Dutriaux, Caroline
    Garbe, Claus
    Yan, Yibing
    Wongchenko, Matthew
    Chang, Ilsung
    Hsu, Jessie J.
    Koralek, Daniel O.
    Rooney, Isabelle
    Ribas, Antoni
    Larkin, James
    [J]. LANCET ONCOLOGY, 2016, 17 (09) : 1248 - 1260
  • [8] Parathyroid hormone-related protein and hypercalcemia in patients with metastatic melanoma - Case report and review
    Attia, P
    Phan, GQ
    Duray, PH
    Rosenberg, SA
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2003, 26 (01): : 42 - 45
  • [9] A MULTIFACTORIAL ANALYSIS OF MELANOMA .4. PROGNOSTIC FACTORS IN 200 MELANOMA PATIENTS WITH DISTANT METASTASES (STAGE III)
    BALCH, CM
    SOONG, SJ
    MURAD, TM
    SMITH, JW
    MADDOX, WA
    DURANT, JR
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1983, 1 (02) : 126 - 134
  • [10] Concurrent Radiotherapy and Ipilimumab Immunotherapy for Patients with Melanoma
    Barker, Christopher A.
    Postow, Michael A.
    Khan, Shaheer A.
    Beal, Kathryn
    Parhar, Preeti K.
    Yamada, Yoshiya
    Lee, Nancy Y.
    Wolchok, Jedd D.
    [J]. CANCER IMMUNOLOGY RESEARCH, 2013, 1 (02) : 92 - 98